PDCD1 and ovarian carcinoma: However, ovarian cancer exhibits a very modest response to anti-PD-1/PD-L1 monotherapy, with responses in approximately 10–15% of chemotherapy-refractory patients and a median progression-free survival of 3–4 months [118,119].